| Description | Nafimidone shows anticonvulsant activity in a rat model of amygdala epilepsy and can be used in the treatment of chronic intractable epilepsy. |
| In vivo | Nafimidone（每日600mg；12位患者）在医院内添加使用了两周。其后，患者每周进行一次评估，持续8周。八位患者的癫痫控制情况得到了33-98%的改善。Nafimidone显著抑制了CBZ和PHT的清除作用，导致九位患者的血浆浓度提高。[3] |
| molecular weight | 236.27 |
| Molecular formula | C15H12N2O |
| CAS | 64212-22-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (232.79 mM) |
| References | 1. Robertson DW, et al. Structure-activity relationships of (arylalkyl)imidazole anticonvulsants: comparison of the (fluorenylalkyl)imidazoles with nafimidone and denzimol. J Med Chem. 1986;29(9):1577-1586. 2. Walker KA, et al. 1-(Naphthylalkyl)-1H-imidazole derivatives, a new class of anticonvulsant agents. J Med Chem. 1981;24(1):67-74. 3. Treiman DM, et al. Efficacy of nafimidone in the treatment of intractable partial seizures: report of a two-center pilot study. Epilepsia. 1985;26(6):607-611. |